PADOAN, ROBERTO
 Distribuzione geografica
Continente #
NA - Nord America 1.663
EU - Europa 335
AS - Asia 158
SA - Sud America 8
Totale 2.164
Nazione #
US - Stati Uniti d'America 1.659
IT - Italia 192
CN - Cina 138
SE - Svezia 38
UA - Ucraina 31
DE - Germania 20
FI - Finlandia 18
GB - Regno Unito 15
IN - India 12
FR - Francia 7
BR - Brasile 5
IE - Irlanda 5
MX - Messico 3
MK - Macedonia 2
PE - Perù 2
SG - Singapore 2
VN - Vietnam 2
BY - Bielorussia 1
CA - Canada 1
CH - Svizzera 1
CL - Cile 1
HK - Hong Kong 1
JP - Giappone 1
NL - Olanda 1
NO - Norvegia 1
PH - Filippine 1
PL - Polonia 1
RO - Romania 1
SM - San Marino 1
TR - Turchia 1
Totale 2.164
Città #
Fairfield 292
Chandler 235
Ashburn 163
Seattle 134
Cambridge 131
Houston 114
Woodbridge 105
Ann Arbor 93
Wilmington 74
Beijing 32
San Diego 32
Padova 31
Medford 29
Princeton 29
Des Moines 22
Guangzhou 22
Helsinki 17
Boardman 10
New York 9
Los Angeles 8
Cagliari 6
Milan 6
Paris 6
Cerea 5
Jinan 5
Palermo 5
Pasian di Prato 5
Tianjin 5
Dublin 4
Nanjing 4
Verona 4
Bologna 3
Ferentino 3
Fuzhou 3
Hefei 3
Kunming 3
London 3
Mogliano Veneto 3
Redwood City 3
Shanghai 3
Stockholm 3
Venice 3
Bollate 2
Chiswick 2
Florence 2
Foggia 2
Fortaleza 2
Ho Chi Minh City 2
Joinville 2
Livorno 2
Mascalucia 2
Mugnano di Napoli 2
Mumbai 2
Nanchang 2
Norwalk 2
Ogden 2
Reston 2
Rhome 2
San Mateo 2
Serrenti 2
Shenyang 2
Singapore 2
Skopje 2
Vasto 2
Washington 2
West Chester 2
Wuhan 2
Akita 1
Arequipa 1
Arezzo 1
Aylesbury 1
Baotou 1
Bari 1
Bergamo 1
Birmingham 1
Bitonto 1
Bolzaneto 1
Bucharest 1
Camponogara 1
Catania 1
Central District 1
Changsha 1
Chicago 1
Chongqing 1
Cuajimalpa 1
Dallas 1
Düsseldorf 1
Ergolding 1
Fondi 1
Gdansk 1
Haikou 1
Hayes 1
Hebei 1
Jiaxing 1
Kilburn 1
Lambeth 1
Lanzhou 1
Lappeenranta 1
Las Vegas 1
Latina 1
Totale 1.753
Nome #
Nasal polyps in eosinophilic granulomatosis with polyangiitis: structured histopathology and CD105 expression 231
Overall Disability Sum Score for Clinical Assessment of Neurological Involvement in Eosinophilic Granulomatosis with Polyangiitis 157
Fully integrated 18f-fdg pet/mr in large vessel vasculitis 128
Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes 119
Cogan's syndrome: new therapeutic approaches in the biological era 114
Update on Vertigo in Autoimmune Disorders, from Diagnosis to Treatment 112
The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU) 111
Diagnostic and prognostic role of renal histopathology in rheumatic diseases 108
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients 96
No differences in nasal tissue inflammatory cells and adhesion molecules (iCAM-1 and vCAM-1) comparing EGPA with eosinophilic chronic sinusitis with polyposis. 83
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors 81
A new cytological approach to improve the final diagnosis of Eosinophilic Granulomatosis with Polyangiitis (EGPA) 73
Fully integrated 18F-FDG PET/MR in large vessel vasculitis 68
PERSISTENT LOW-GRADE VASCULAR INFLAMMATION IN LARGE VESSEL VASCULITIS: A LONGITUDINAL STUDY USING FULLY INTEGRATED 18F-FDG PET/MR 64
Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis 64
Health-Related Quality of Life in Patients With ANCA-Associated Vasculitis and Sinonasal Involvement: A Single-Center Cross-Sectional Study 62
Neutrophil infiltrates and eosinophil aggregates in chronic rhinosinusitis with nasal polyps and EGPA. 61
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study 52
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) 51
Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study 41
Renal involvement at baseline can predict major renal relapse in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis 39
IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis 39
Ear, nose, and throat in ANCA-associated vasculitis: a comprehensive review 39
Disease and treatment-related morbidity in young and elderly patients with granulomatosis with polyangiitis and microscopic polyangiitis 39
New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort 27
Biologic therapy in relapsing polychondritis: navigating between options 27
Current clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis 27
Whipple's aortitis 25
Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis 24
Il ruolo della 18F FDG-PET/RM nella diagnosi e gestione dei pazienti affetti da vasculiti dei grossi vasi 22
Management of critically ill surgical patients 22
Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis 11
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study 7
Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies 2
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence 1
Totale 2.227
Categoria #
all - tutte 8.853
article - articoli 8.759
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.612


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201965 0 0 0 0 0 0 0 0 0 10 29 26
2019/2020428 24 38 18 59 36 23 66 38 48 21 41 16
2020/2021516 24 153 69 39 15 16 12 28 26 45 47 42
2021/2022476 14 35 39 34 34 60 34 38 42 15 26 105
2022/2023415 77 57 20 62 49 39 9 20 35 5 36 6
2023/2024302 6 24 32 18 22 48 44 31 31 46 0 0
Totale 2.227